STOCK TITAN
  1. Home
  2. News
  3. ABVC

ABVC BioPharma Inc - ABVC STOCK NEWS

Welcome to our dedicated news page for ABVC BioPharma (Ticker: ABVC), a resource for investors and traders seeking the latest updates and insights on ABVC BioPharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ABVC BioPharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ABVC BioPharma's position in the market.

News
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
Rhea-AI Summary
ABVC BioPharma enrolls 60 subjects in ADHD Phase IIb study, with 53 completing the eight-week study. Phase IIa achieved primary endpoints. Global ADHD treatment market valued at $16.13B in 2022, expected to reach $32.14B by 2030 with CAGR of 7.1%[1].
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
clinical trial
-
News
ABVC Executes Cooperation Agreement for Strategic Investments
Rhea-AI Summary
ABVC BioPharma, Inc. enters Cooperation Agreement with Zhonghui United Technology Group, exchanging 20% ownership stake in real estate for $7.4 million worth of ABVC common stock at $20 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
none
-
News
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
Rhea-AI Summary
ABVC BioPharma regains compliance with Nasdaq minimum bid price requirement. The company received a letter from the Nasdaq Listing Qualifications Department stating that it had regained compliance with the minimum bid price requirement. The closing bid price of the company's common stock was at $1.00 per share or greater from July 25 to August 7, 2023. This matter is now closed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.82%
Tags
none
News
ABVC Corporate Update and CEO's Letter to Shareholders
Rhea-AI Summary
ABVC BioPharma, a clinical-stage biopharmaceutical company, has published a corporate update and letter to shareholders from its CEO, Dr. Uttam Patil. The update highlights the progress made in their diverse pipeline, including the development of a controlled-release tablet formulation for their neurological programs and advancements in their ophthalmology, neurology, and oncology/hematology trials. ABVC also signed a licensing deal with a Chinese pharmaceutical company, Xinnovation Therapeutics, which could bring in $20 million in income. The company is actively working on becoming a one-stop solution for pharmaceutical services and is planning an acquisition of real estate assets in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.47%
Tags
none
-
News
ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration
Rhea-AI Summary
ABVC BioPharma plans to set up a pilot GMP facility in Taiwan to produce Vitargus®, a product for retinal detachment surgery. The facility aims to optimize manufacturing processes and handle global market supply. The global market for retinal surgery devices is expected to reach $4.3 billion by 2029.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
none
-
News
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales
Rhea-AI Summary
ABVC Biopharma, Inc. has signed a term sheet with Xinnovation Therapeutics for the exclusive licensing of ABV-1504 and ABV-1505 in mainland China. The deal includes development, manufacturing, marketing, and distribution rights, with potential aggregate income of $20 million for ABVC. The final agreement is expected to be signed within one year. ABVC expects royalty payments ranging from 5% to 12% based on projected annual net sales, which could bring in revenue of $50 million annually and $1 billion during the patent life of the products. The agreement is subject to closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
44.98%
Tags
none
News
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
Rhea-AI Summary
ABVC BioPharma closes on $1.75 million securities purchase agreement with institutional investor
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
offering
-
News
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
Rhea-AI Summary
ABVC BioPharma, Inc. (NASDAQ: ABVC) Announces $1.75 Million Registered Direct Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.73%
Tags
offering
-
News
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
Rhea-AI Summary
ABVC BioPharma signs term sheet for partnership with Zhonghui United Technology Group. Partnership aims to advance development of health and wellness base in Chengdu, China. Acquisition of real estate assets estimated at $7.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40%
Tags
acquisition
News
ABVC BioPharma Announces Reverse Stock Split
Rhea-AI Summary
ABVC BioPharma announces reverse stock split to regain compliance with Nasdaq listing rules
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
Stock ABVC logo
ABVC BioPharma Inc

Nasdaq:ABVC

ABVC Rankings

#5333 Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ABVC Stock Data

11.83M
6.80M
26.97%
2.43%
12.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Fremont

About ABVC

american brivision (holding) corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the united states. the company is developing abv-1501, a combination therapy for triple negative breast cancer; abv-1504 for major depressive disorders; abv-1505 for attention deficit hyperactivity disorder; abv-1703 for the treatment of pancreatic cancer; abv-1702 to treat myelodysplastic syndromes; and abv-1601 for treating depression in cancer patients. it has a co-development agreement with rgene corporation; collaboration agreement with biohopeking corporation to develop abv-1501; and collaborative agreement with biofirst corporation to co-develop bfc-1401 vitreous substitute for vitrectom; and license with biofirst corporation to research and develop a medical device, abv-1701 vitargus for the treatment of retinal detachment or vitreous hemorrhage. the company was founded in 2015 and is based in fremont, california. american br